Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 3 1Phase 1 1

Status

Completed 4Active not recruiting 1

Sponsor Class

INDUSTRY 4NIH 1

Study Type

Interventional 5

Sponsor

Cancer Type

Other hematologic neoplasm 3Thoracic 1Lymphoid 1Dermatologic 1

Conditions

Leukemia, Myeloid, Acute 2Pathologic Complete Response 1Neoplasms 1Lymphoma, T-Cell, Peripheral 1Lymphoma, T-Cell, Cutaneous 1Hematologic Neoplasms 1Hematologic Diseases 1Carcinoma, Non-Small-Cell Lung 1

Interventions

pembrolizumab 304Carboplatin 155Nivolumab 155Cisplatin 140Cyclophosphamide 132Paclitaxel 128Magnetic Resonance Spectroscopy 98Specimen Handling 95Radiotherapy 91Gemcitabine 87Dexamethasone 85Biopsy 81Ipilimumab 78Doxorubicin 76Docetaxel 75Rituximab 70Etoposide 67atezolizumab 62durvalumab 61Radiation 60Lenalidomide 59Pemetrexed 58Taxes 57Bevacizumab 55Prednisone 55fludarabine 54olaparib 54Vincristine 50Cytarabine 48Fluorouracil 48

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Has results × cc-486 × 1 year × Clear all
NCT02494258 2026-04-02

A Study to Evaluate Long-term Safety of CC-486 (Oral Azacitidine) in Subjects With Hematological Disorders

Celgene

Phase 2 Completed
5 enrolled 10 charts
Other hematologic neoplasm

Hematologic Diseases, Neoplasms, Hematologic Neoplasms

NCT05197426 2026-02-11

A Study to Compare the Efficacy and Safety of Oral Azacitidine Plus Best Supportive Care Versus Best Supportive Care as Maintenance Therapy in Japanese Participants With Acute Myeloid Leukemia (AML) in Complete Remission

Bristol-Myers Squibb

Phase 2 Active not recruiting
19 enrolled 24 charts
Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT04447027 2026-01-30

Romidepsin, CC-486 (5-azacitidine), Dexamethasone, and Lenalidomide (RAdR) for Relapsed/Refractory T-cell Malignancies

National Institutes of Health Clinical Center (CC)

Phase 1 Completed
26 enrolled 24 charts
DermatologicLymphoid

Lymphoma, T-Cell, Cutaneous, Lymphoma, T-Cell, Peripheral

NCT02546986 2025-08-08

Safety and Efficacy Study of CC-486 With MK-3475 to Treat Locally Advanced or Metastatic Non-small Cell Lung Cancer

Celgene

Phase 2 Completed
100 enrolled 27 charts
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT01757535 2025-07-08

QUAZAR AML-001

Celgene

Phase 3 Completed
472 enrolled 24 charts 1 FDA
Other hematologic neoplasm

Pathologic Complete Response, Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡